AAP
HRTX icon

Arax Advisory Partners’s Heron Therapeutics HRTX Stock Holding History

Arax Advisory Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94K Buy
6,890
+6,875
+45,833% +$5.51K ﹤0.01% 4721
2026
Q1 		$212 Sell
15
-114
-88% -$132 ﹤0.01% 3531
2025
Q4 		$168 Sell
129
-33,245
-100% -$41K ﹤0.01% 3747
2025
Q3 		$42.1K Buy
+33,374
New +$52.9K ﹤0.01% 1906
2025
Q1 		– Sell
-1,035
Closed -$1.58K – 2850
2024
Q4 		$1.58K Sell
1,035
-60
-5% -$97 ﹤0.01% 2058
2024
Q3 		$2.18K Hold
1,095
– – ﹤0.01% 2035
2024
Q2 		$3.83K Buy
+1,095
New +$3.36K ﹤0.01% 1707

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Arax Advisory Partners's HRTX Position: Q2 2026 in Review

Arax Advisory Partners increased its Heron Therapeutics (HRTX) stake by 45,833% in Q2 2026, buying an estimated $5.51K and bringing the position to 6,890 shares worth $2.94K. The position accounts for ﹤0.01% of the portfolio, ranked #4721.

Arax Advisory Partners first reported a position in HRTX in Q2 2024 and has held it in 7 quarters since. The position peaked at $42.1K in Q3 2025. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Arax Advisory Partners held 6,890 shares of Heron Therapeutics worth $2.94K as of Q2 2026.
  • Arax Advisory Partners bought 6,875 Heron Therapeutics shares in Q2 2026, an estimated $5.51K.
  • Heron Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4721 holding.
  • Arax Advisory Partners first reported a position in Heron Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Heron Therapeutics position peaked at $42.1K in Q3 2025.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.